ARTICLE AD BOX
South Korea's Penetrium Bioscience said Wednesday that the company would start a clinical test combining its investigational cancer drug Penetrium with Merck's immunotherapy Keytruda.
South Korea's Penetrium Bioscience said Wednesday that the company would start a clinical test combining its investigational cancer drug Penetrium with Merck's immunotherapy Keytruda.